Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment

Transfusion Medicine and Hemotherapy

Volumn 43, Issue 2, 2016, Pages 120-132

  Lotfi, Ramin ^a   Kaltenmeier, Christof ^b   Lotze, Michael T ^b   Bergmann, Christoph ^c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PATTERN RECOGNITION RECEPTOR;

APOPTOSIS; AUTOPHAGY; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL DEATH; CELL MATURATION; DENDRITIC CELL; EOSINOPHIL; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFLAMMATION; INFLAMMATORY CELL; MESENCHYMAL STROMA CELL; MONOCYTE; NECROPTOSIS; NECROSIS; NEOPLASM; OXIDATION; REGULATORY T LYMPHOCYTE; REVIEW; STROMA CELL; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WOUND HEALING;

EID: 84961219127     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000444941     Document Type: Review

References (206)

1. Perwez Hussain S, Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-2380.
2. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-106.
3. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF: Dissecting the tumor myeloid compartment reveals rare activating antigenpresenting cells critical for T cell immunity. Cancer Cell 2014; 26: 638-652.
4. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM: Macrophage IL-10 blocks CD8+ T celldependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014; 26: 623-637.
5. Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, Leitch AM, Johnson TM, De-Berardinis RJ, Morrison SJ: Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 2015; 527: 186-191.
6. Harris IS, Brugge JS: Cancer: The enemy of my enemy is my friend. Nature 2015; 527: 170-171.
7. Idrovo JP, Jacob A, Yang WL, Wang Z, Yen HT, Nicastro J, Coppa GF, Wang P: A deficiency in cold-inducible RNA-binding protein accelerates the inflammation phase and improves wound healing. Int J Mol Med 2016; 10.
8. Zhou Y, Dong H, Zhong Y, Huang J, Lv J, Li J: The Cold-Inducible RNA-Binding Protein (CIRP) Level in peripheral blood predicts sepsis outcome. PLoS One 2015; 10:e0137721.
9. Godwin A, Yang WL, Sharma A, Khader A, Wang Z, Zhang F, Nicastro J, Coppa GF, Wang P: Blocking coldinducible RNA-binding protein protects liver from ischemia-reperfusion injury. Shock 2015; 43: 24-30.
10. Qiang X, Yang WL, Wu R, Zhou M, Jacob A, Dong W, Kuncewitch M, Ji Y, Yang H, Wang H, Fujita J, Nicastro J, Coppa GF, Tracey KJ, Wang P: Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis. Nat Med 2013; 19: 1489-1495.
11. Vogel S, Bodenstein R, Chen Q, Feil S, Feil R, Rheinlaender J, Schaffer TE, Bohn E, Frick JS, Borst O, Munzer P, Walker B, Markel J, Csanyi G, Pagano PJ, Loughran P, Jessup ME, Watkins SC, Bullock GC, Sperry JL, Zuckerbraun BS, Billiar TR, Lotze MT, Gawaz M, Neal MD: Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest 2015; 125: 4638-4654.
12. Chen M, Liu Y, Varley P, Chang Y, He XX, Huang H, Tang D, Lotze MT, Lin J, Tsung A: High-mobility group box 1 promotes hepatocellular carcinoma progression through miR-21-mediated matrix metalloproteinase activity. Cancer Res 2015; 75: 1645-1656.
13. Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian D, Lotze M, Tang D, Tsung A: Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol 2015; 63: 114-121.
14. Zhu X, Messer JS, Wang Y, Lin F, Cham CM, Chang J, Billiar TR, Lotze MT, Boone DL, Chang EB: Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. J Clin Invest 2015; 125: 1098-1110.
15. Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, Huang J, Yu Y, Fan XG, Yan Z, Sun X, Wang H, Wang Q, Tsung A, Billiar TR, Zeh HJ, III, Lotze MT, Tang D: HMGB1 in health and disease. Mol Aspects Med 2014; 40: 1-116.
16. Yang L, Xie M, Yang M, Yu Y, Zhu S, Hou W, Kang R, Lotze MT, Billiar TR, Wang H, Cao L, Tang D: PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun 2014; 5: 4436.
17. Lotfi R, Lee JJ, Lotze MT: Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother 2007; 30: 16-28.
18. Lotfi R, Schrezenmeier H, Lotze MT: Immunotherapy for cancer: promoting innate immunity. Front Biosci 2009; 14: 818-832.
19. Lotfi R, Wiegmann DS, Asseck L, Erle A, Yildiz T, Jahrsdörfer B, Schrezenmeier H: Necrosis-associated factors (DAMPs) including S100A4 used to pulse dendritic cells (DCs) induce regulatory T cells. J Cell Sci Ther 2012; 134: 2.
20. Zeh HJ, III, Lotze MT: Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 2005; 28: 1-9.
21. Lotfi R, Herzog GI, DeMarco RA, Beer-Stolz D, Lee JJ, Rubartelli A, Schrezenmeier H, Lotze MT: Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J Immunol 2009; 183: 5023-5031.
22. Lotfi R, Eisenbacher J, Solgi G, Fuchs K, Yildiz T, Nienhaus C, Rojewski MT, Schrezenmeier H: Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material. Eur J Immunol 2011; 41: 2021-2028.
23. Eisenbacher JL, Schrezenmeier H, Jahrsdorfer B, Kaltenmeier C, Rojewski MT, Yildiz T, Beyer T, Erle A, Wiegmann DS, Grassl S, Hang R, Korper S, Wiesneth M, Lotze MT, Lotfi R: S100A4 and uric acid promote mesenchymal stromal cell induction of IL-10+/IDO+ lymphocytes. J Immunol. 2014; 192: 6102-6110.
24. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
25. Young HE, Steele TA, Bray RA, Hudson J, Floyd JA, Hawkins K, Thomas K, Austin T, Edwards C, Cuzzourt J, Duenzl M, Lucas PA, Black AC Jr: Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat Rec 2001; 264: 51-62.
26. Gregory CA, Prockop DJ, Spees JL: Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. Exp Cell Res 2005; 306: 330-335.
27. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309-313.
28. Taniguchi IE, Gonzalez-Nieto D, Ghiaur G, Dunn SK, Ficker AM, Murali B, Madhu M, Gutstein DE, Fishman GI, Barrio LC, Cancelas JA: Connexin-43 prevents hematopoietic stem cell senescence through transfer of reactive oxygen species to bone marrow stromal cells. Proc Natl Acad Sci U S A 2012; 109: 9071-9076.
29. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
30. Matzinger P: An innate sense of danger. Ann N Y Acad Sci 2002; 961: 341-342.
31. Odemuyiwa SO, Ghahary A, Li Y, Puttagunta L, Lee JE, Musat-Marcu S, Moqbel R: Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J Immunol 2004; 173: 5909-5913.
32. Hung SC, Deng WP, Yang WK, Liu RS, Lee CC, Su TC, Lin RJ, Yang DM, Chang CW, Chen WH, Wei HJ, Gelovani JG: Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 2005; 11: 7749-7756.
33. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-563.
34. Meng E, Guo Z, Wang H, Jin J, Wang J, Wang H, Wu C, Wang L: High mobility group box 1 protein inhibits the proliferation of human mesenchymal stem cells and promotes their migration and differentiation along osteoblastic pathway. Stem Cells Dev 2008; 17: 805-813.
35. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, Devera ME, Liang X, Tor M, Billiar T: The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007; 220: 60-81.
36. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA: Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29: 21-32.
37. Janeway CA, Jr.: Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54: 1-13.
38. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT: PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev 2012; 249: 158-175.
39. Kang R, Zhang Q, Zeh HJ, III, Lotze MT, Tang D: HMGB1 in cancer: good, bad, or both? Clin Cancer Res 2013; 19: 4046-4057.
40. Steinman RM: Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30: 1-22.
41. Schuler G, Steinman RM: Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985; 161: 526-546.
42. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W: Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004; 64: 5535-5538.
43. Baleeiro RB, Anselmo LB, Soares FA, Pinto CA, Ramos O, Gross JL, Haddad F, Younes RN, Tomiyoshi MY, Bergami-Santos PC, Barbuto JA: High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-alpha in lung cancer. Cancer Immunol Immunother 2008; 57: 1335-1345.
44. Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, Zhong H, Han B, Ferris RL: Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 2006; 25: 333-356.
45. Whiteside TL: The role of immune cells in the tumor microenvironment. Cancer Treat Res 2006; 130: 103-124.
46. Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904-5912.
47. Mantovani A, Sozzani S, Locati M, Schioppa T, Saccani A, Allavena P, Sica A: Infiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Novartis Found Symp 2004; 256: 137-145.
48. Liu Q, Zhang C, Sun A, Zheng Y, Wang L, Cao X: Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol 2009; 182: 6207-6216.
49. Benencia F, Sprague L, McGinty J, Pate M, Muccioli M: Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol 2012; 2012: 425476.
50. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD: Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9: 1225-1235.
51. Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, Wagner DS, Katsaros D, Caroll R, Coukos G: Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004; 10: 950-958.
52. Gottfried E, Kreutz M, Haffner S, Holler E, Iacobelli M, Andreesen R, Eissner G: Differentiation of human tumour-associated dendritic cells into endothelial-like cells: an alternative pathway of tumour angiogenesis. Scand J Immunol 2007; 65: 329-335.
53. Fernandez PB, Lucibello FC, Zuzarte M, Lutjens P, Muller R, Havemann K: Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur J Cell Biol 2001; 80: 99-110.
54. Lu J, Liu K, Zhao J, Zhao J, Ma J, Yang H, Huang Y, Qin Z, Bai R, Jiang L, Lv F, Li P, Yan W, Zhao M, Dong Z: VEGF-A not Ang2 mediates endothelial-like differentiation of immature DCs by ERK1/2 signaling in the microenvironment of human colon adenocarcinoma. Int J Oncol 2011; 38: 1579-1588.
55. Lu J, Zhao J, Liu K, Zhao J, Yang H, Huang Y, Qin Z, Bai R, Li P, Ma J, Yan W, Zhao M, Dong Z: MAPK/ERK1/2 signaling mediates endothelial-like differentiation of immature DCs in the microenvironment of esophageal squamous cell carcinoma. Cell Mol Life Sci 2010; 67: 2091-2106.
56. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6: 1755-1766.
57. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP, O'Garra A, Trinchieri G, Caux C: Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002; 196: 541-549.
58. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S, Berenzi A, Cella M, Colonna M: Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003; 200: 255-268.
59. Ugolini C, Basolo F, Proietti A, Vitti P, Elisei R, Miccoli P, Toniolo A: Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. Thyroid 2007; 17: 389-393.
60. Feijoo E, Alfaro C, Mazzolini G, Serra P, Penuelas I, Arina A, Huarte E, Tirapu I, Palencia B, Murillo O, Ruiz J, Sangro B, Richter JA, Prieto J, Melero I: Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 2005; 116: 275-281.
61. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM: Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112: 610-618.
62. Dannull J, Nair S, Su Z, Boczkowski D, DeBeck C, Yang B, Gilboa E, Vieweg J: Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 2005; 105: 3206-3213.
63. Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR: Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008; 68: 7684-7691.
64. Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G: A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 2013; 19: 4801-4815.
65. Vakkila J, Lotze MT: Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004; 4: 641-648.
66. Schmidt-Hansen B, Ornas D, Grigorian M, Klingelhofer J, Tulchinsky E, Lukanidin E, Ambartsumian N: Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 2004; 23: 5487-5495.
67. Belot N, Pochet R, Heizmann CW, Kiss R, Decaestecker C: Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton. Biochim Biophys Acta 2002; 1600: 74-83.
68. Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, Pietrzynski G, Stanimirovic D, Alakhov V: Metastasis-associated protein S100A4 induces angiogenesis through interaction with annexin II and accelerated plasmin formation. J Biol Chem 2005; 280: 20833-20841.
69. Schmidt-Hansen B, Klingelhofer J, Grum-Schwensen B, Christensen A, Andresen S, Kruse C, Hansen T, Ambartsumian N, Lukanidin E, Grigorian M: Functional significance of metastasis-inducing S100A4(Mts1) in tumorstroma interplay. J Biol Chem 2004; 279: 24498-24504.
70. Boye K, Maelandsmo GM: S100A4 and metastasis: A small actor playing many roles. Am J Pathol 2010; 176: 528-535.
71. Mencia N, Selga E, Rico I, de Almagro MC, Villalobos X, Ramirez S, Adan J, Hernandez JL, Noe V, Ciudad CJ: Overexpression of S100A4 in human cancer cell lines resistant to methotrexate. BMC Cancer 2010; 10: 250-210.
72. Wang HY, Zhang JY, Cui JT, Tan XH, Li WM, Gu J, Lu YY: Expression status of S100A14 and S100A4 correlates with metastatic potential and clinical outcome in colorectal cancer after surgery. Oncol Rep 2010; 23: 45-52.
73. Kang YG, Jung CK, Lee A, Kang WK, Oh ST, Kang CS: Prognostic significance of S100A4 mRNA and protein expression in colorectal cancer. J Surg Oncol 2012; 105: 119-124.
74. Rothenberg ME, Mishra A, Brandt EB, Hogan SP: Gastrointestinal eosinophils. Immunol Rev 2001; 179: 139-155.
75. Jones RL, Hannan NJ, Kaitu'u TJ, Zhang J, Salamonsen LA: Identification of chemokines important for leukocyte recruitment to the human endometrium at the times of embryo implantation and menstruation. J Clin Endocrinol Metab 2004; 89: 6155-6167.
76. Matthews AN, Friend DS, Zimmermann N, Sarafi MN, Luster AD, Pearlman E, Wert SE, Rothenberg ME: Eotaxin is required for the baseline level of tissue eosinophils. Proc of the Natl Acad Sci U S A 1998; 95: 6273-6278.
77. Yang J, Torio A, Donoff RB, Gallagher GT, Egan R, Weller PF, Wong DT: Depletion of eosinophil infiltration by anti-IL-5 monoclonal antibody (TRFK-5) accelerates open skin wound epithelial closure. Am J Pathol 1997; 151: 813-819.
78. Samoszuk M: Eosinophils and human cancer. Histol Histopathol 1997; 12: 807-812.
79. Lee JJ, Lee NA: Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function? Clin Exp Allergy 2005; 35: 986-994.
80. Afshar K, Vucinic V, Sharma OP: Eosinophil cell: pray tell us what you do! Curr Opin Pulm Med 2007; 13: 414-421
81. Lotfi R, Lotze MT: Eosinophils induce DC maturation, regulating immunity. J Leukoc Biol 2008; 83: 456-460.
82. Nagata M, Sedgwick JB, Bates ME, Kita H, Busse WW: Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation. J Immunol 1995; 155: 2194-2202.
83. Bandeira-Melo C, Woods LJ, Phoofolo M, Weller PF: Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med 2002; 196: 841-850.
84. Henderson WR, Harley JB, Fauci AS: Arachidonic acid metabolism in normal and hypereosinophilic syndrome human eosinophils: generation of leukotrienes B4, C4, D4 and 15-lipoxygenase products. Immunology 1984; 51: 679-686.
85. Turk J, Maas RL, Brash AR, Roberts LJ, Oates JA: Arachidonic acid 15-lipoxygenase products from human eosinophils. J Biol Chem 1982; 257: 7068-7076.
86. Bruijnzeel P, Kok P, Kijne G, Verhagen J: Leukotriene synthesis by isolated granulocytes from intrinsic and extrinsic asthmatics and age-matched controls. Agents Actions Suppl 1989; 28: 191-194.
87. Lee T, Lenihan DJ, Malone B, Roddy LL, Wasserman SI: Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem 1984; 259: 5526-5530.
88. Hay DW, Torphy TJ, Undem BJ: Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995; 16: 304-309.
89. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ: Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286: 264-265.
90. Busse WW: Leukotrienes and inflammation. Am J Respir Crit Care Med 1998; 157:S210-S213; discussion S247-248.
91. Akuthota P, Wang H, Weller PF: Eosinophils as antigen-presenting cells in allergic upper airway disease. Curr Opin Allergy Clin Immunol 2010; 10: 14-19.
92. Lucey DR, Dorsky DI, Nicholson-Weller A, Weller PF: Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120. J Exp Med 1989; 169: 327-332.
93. Mattes J, Yang M, Mahalingam S, Kuehr J, Webb DC, Simson L, Hogan SP, Koskinen A, McKenzie AN, Dent LA, Rothenberg ME, Matthaei KI, Young IG, Foster PS: Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 2002; 195: 1433-1444.
94. Padigel UM, Lee JJ, Nolan TJ, Schad GA, Abraham D: Eosinophils can function as antigen-presenting cells to induce primary and secondary immune responses to Strongyloides stercoralis. Infect Immun 2006; 74: 3232-3238.
95. Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF: Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest 2000; 105: 945-953.
96. Weller PF, Rand TH, Barrett T, Elovic A, Wong DT, Finberg RW: Accessory cell function of human eosinophils. HLA-DR-dependent, MHC-restricted antigenpresentation and IL-1 alpha expression. J Immunol 1993; 150: 2554-2562.
97. Astigiano S, Morandi B, Costa R, Mastracci L, D'Agostino A, Ratto GB, Melioli G, Frumento G: Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 2005; 7: 390-396.
98. Braun D, Longman RS, Albert ML: A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005; 106: 2375-2381.
99. Schramm C, Huber S, Protschka M, Czochra P, Burg J, Schmitt E, Lohse AW, Galle PR, Blessing M: TGFbeta regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo. Int Immunol 2004; 16: 1241-1249.
100. Iwakura Y, Ishigame H: The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116: 1218-1222.
101. Kim MR, Manoukian R, Yeh R, Silbiger SM, Danilenko DM, Scully S, Sun J, DeRose ML, Stolina M, Chang D, Van GY, Clarkin K, Nguyen HQ, Yu YB, Jing S, Senaldi G, Elliott G, Medlock ES: Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood 2002; 100: 2330-2340.
102. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R, Elias J, Chakir J: IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108: 430-438.
103. Stenfeldt AL, Wenneras C: Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. Immunology 2004; 112: 605-614.
104. Cormier SA, Larson KA, Yuan S, Mitchell TL, Lindenberger K, Carrigan P, Lee NA, Lee JJ: Mouse eosinophil-associated ribonucleases: A unique subfamily expressed during hematopoiesis. Mamm Genome 2001; 12: 352-361.
105. Cormier SA, Taranova AG, Bedient C, Nguyen T, Protheroe C, Pero R, Dimina D, Ochkur SI, O'Neill K, Colbert D, Lombari TR, Constant S, McGarry MP, Lee JJ, Lee NA: Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol 2006; 79: 1131-1139.
106. Cuschieri A, Talbot IC, Weeden S: Influence of pathological tumour variables on long-term survival in resectable gastric cancer. Br J Cancer 2002; 86: 674-679.
107. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A: Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000; 88: 1544-1548.
108. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, van Krieken JH: Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-A histopathological and immunohistochemical study. BMC Cancer 2001; 1: 7.
109. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F: Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999; 189: 487-495.
110. Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG, Kimball PM, Boohaker EA: Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 1983; 43: 2997-3000.
111. Petreccia DC, Nauseef WM, Clark RA: Respiratory burst of normal human eosinophils. J Leukoc Biol 1987; 41: 283-288.
112. Someya A, Nishijima K, Nunoi H, Irie S, Nagaoka I: Study on the superoxide-producing enzyme of eosinophils and neutrophils-comparison of the NADPH oxidase components. Arch Biochem Biophys 1997; 345: 207-213.
113. Yagisawa M, Yuo A, Yonemaru M, Imajoh-Ohmi S, Kanegasaki S, Yazaki Y, Takaku F: Superoxide release and NADPH oxidase components in mature human phagocytes: correlation between functional capacity and amount of functional proteins. Biochem Biophys Res Commun 1996; 228: 510-516.
114. Haskell MD, Moy JN, Gleich GJ, Thomas LL: Analysis of signaling events associated with activation of neutrophil superoxide anion production by eosinophil granule major basic protein. Blood 1995; 86: 4627-4637.
115. Moy JN, Gleich GJ, Thomas LL: Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release. J Immunol 1990; 145: 2626-2632.
116. Conejo-Garcia JR, Benencia F, Courreges MC, Gimotty PA, Khang E, Buckanovich RJ, Frauwirth KA, Zhang L, Katsaros D, Thompson CB, Levine B, Coukos G: Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28-antitumor T cells. Cancer Res 2004; 64: 2175-2182.
117. Costello RT, Fauriat C, Sivori S, Marcenaro E, Olive D: NK cells: innate immunity against hematological malignancies? Trends Immunol 2004; 25: 328-333.
118. Kataoka S, Konishi Y, Nishio Y, Fujikawa-Adachi K, Tominaga A: Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. DNA Cell Biol 2004; 23: 549-560.
119. Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE: IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol 2006; 176: 1490-1497.
120. Goldman M, Le MA, Braun M, Flamand V, Abramowicz D: A role for eosinophils in transplant rejection. Trends Immunol 2001; 22: 247-251.
121. Le MA, Surquin M, Demoor FX, Noel JC, Nahori MA, Pretolani M, Flamand V, Braun MY, Goldman M, Abramowicz D: IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice. J Immunol 1999; 163: 3778-3784.
122. Huland E, Huland H: Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol 1992; 118: 463-467.
123. Simon HU, Plotz S, Simon D, Seitzer U, Braathen LR, Menz G, Straumann A, Dummer R, Levi-Schaffer F: Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol 2003; 33: 834-839.
124. Sosman JA, Bartemes K, Offord KP, Kita H, Fisher SG, Kefer C, Ellis TA, Fisher RI, Higgins TJ, Gleich GJ: Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res 1995; 1: 805-812.
125. Tepper RI, Coffman RL, Leder P: An eosinophildependent mechanism for the antitumor effect of interleukin-4. Science 1992; 257: 548-551.
126. Bristol JA, Zhu M, Ji H, Mina M, Xie Y, Clarke L, Forry-Schaudies S, Ennist DL: In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 2003; 7: 755-764.
127. Rivoltini L, Viggiano V, Spinazze S, Santoro A, Colombo MP, Takatsu K, Parmiani G: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 1993; 54: 8-15.
128. Wong HL, Costa GL, Lotze MT, Wahl SM: Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo. J Exp Med 1993; 177: 775-781.
129. Tepper RI, Pattengale PK, Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503-512.
130. Tepper RI: The eosinophil-mediated antitumor activity of interleukin-4. J Allergy Clin Immunol 1994; 94: 1225-1231.
131. Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musiani P, Modesti A, Cavallo F, Di PF, Novelli F, Forni G: An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994; 153: 5659-5673.
132. Sacco M, Benedetti S, Cato EM, Caniatti M, Ceruti R, Scanziani E, Pirola B, Villa A, Finocchiaro G, Vezzoni P: Retrovirus-mediated IL-4 gene therapy in spontaneous adenocarcinomas from MMTV-neu transgenic mice. Gene Ther 1999; 6: 1893-1897.
133. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
134. Shevach EM: Mechanisms of foxp3+ T regulatory cellmediated suppression. Immunity 2009; 30: 636-645.
135. Raimondi G, Turner MS, Thomson AW, Morel PA: Naturally occurring regulatory T cells: recent insights in health and disease. Crit Rev Immunol 2007; 27: 61-95.
136. Strauss L, Bergmann C, Whiteside TL: Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer 2007; 121: 2473-2483.
137. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St GB, Clayberger C, Soper DM, Ziegler SF, Bluestone JA: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-1711.
138. Kleinewietfeld M, Starke M, Di MD, Borsellino G, Battistini L, Rotzschke O, Falk K: CD49d provides access to 'untouched' human Foxp3+ Treg free of contaminating effector cells. Blood 2009; 113: 827-836.
139. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY: Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007; 445: 771-775.
140. Sakaguchi S, Yamaguchi T, Nomura T, Ono M: Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787.
141. Roncarolo MG, Gregori S: Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008; 38: 925-927.
142. Polansky JK, Schreiber L, Thelemann C, Ludwig L, Kruger M, Baumgrass R, Cording S, Floess S, Hamann A, Huehn J: Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells. J Mol Med (Berl) 2010; 88: 1029-1040.
143. Ohkura N, Kitagawa Y, Sakaguchi S: Development and maintenance of regulatory T cells. Immunity 2013; 38: 414-423.
144. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC: CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16: 311-323.
145. Josefowicz SZ, Lu LF, Rudensky AY: Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30: 531-564.
146. Fife BT, Bluestone JA: Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166-182.
147. Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL: Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008; 180: 2967-2980.
148. Bilate AM, Lafaille JJ: Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol 2012; 30: 733-758.
149. Lin WW, Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183.
150. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J: Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008; 32: 527-535.
151. Blay J, White TD, Hoskin DW: The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997; 57: 2602-2605.
152. Chen W, Konkel JE: TGF-beta and 'adaptive' Foxp3(+) regulatory T cells. J Mol Cell Biol 2010; 2: 30-36.
153. Kalinski P: Regulation of immune responses by prostaglandin E2. J Immunol 2012; 188: 21-28.
154. Wang D, Dubois RN: Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181-193.
155. Munn DH, Mellor AL: Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117: 1147-1154.
156. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-1274.
157. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Jackson EK, Johnson JT, Gorelik E, Lang S, Whiteside TL: Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010; 285: 27571-27580.
158. Whiteside TL: Immune responses to malignancies. J Allergy Clin Immunol 2010; 125(suppl 2):S272-S283.
159. Ferrone S, Whiteside TL: Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007; 16: 755-774, viii.
160. Malmberg KJ, Arulampalam V, Ichihara F, Petersson M, Seki K, Andersson T, Lenkei R, Masucci G, Pettersson S, Kiessling R: Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol 2001; 1672595-2601.
161. Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. Nat Rev Immunol 2008; 8: 523-532.
162. Mahic M, Yaqub S, Johansson CC, Tasken K, Aandahl EM: FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006; 177: 246-254.
163. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL: Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007; 67(18):8865-8873.
164. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ: Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27: 635-646.
165. Whiteside TL, Mandapathil M, Szczepanski M, Szajnik M: Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer 2011; 98:E25-E31.
166. Nakamura K, Kitani A, Strober W: Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194: 629-644.
167. Blakytny R, Erkell LJ, Brunner G: Inactivation of active and latent transforming growth factor beta by free thiols: potential redox regulation of biological action. Int J Biochem Cell Biol 2006; 38: 1363-1373.
168. Sakaguchi S, Setoguchi R, Yagi H, Nomura T: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease. Curr Top Microbiol Immunol 2006; 305: 51-66.
169. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-betadependent manner. J Exp Med 2005; 202: 1075-1085.
170. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA: Role of LAG-3 in regulatory T cells. Immunity 2004; 21: 503-513.
171. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA: Role of LAG-3 in regulatory T cells. Immunity 2004; 21: 503-513.
172. Joosten SA, van Meijgaarden KE, Savage ND, de BT, Triebel F, van der Wal A, de HE, Klein MR, Geluk A, Ottenhoff TH: Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci U S A 2007; 104: 8029-8034.
173. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P: Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4: 1206-1212.
174. von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6: 338-344.
175. Suthanthiran M, Anderson ME, Sharma VK, Meister A: Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc Natl Acad Sci U S A 1990; 87: 3343-3347.
176. Ishii T, Sugita Y, Bannai S: Regulation of glutathione levels in mouse spleen lymphocytes by transport of cysteine. J Cell Physiol 1987; 133: 330-336.
177. Banjac A, Perisic T, Sato H, Seiler A, Bannai S, Weiss N, Kolle P, Tschoep K, Issels RD, Daniel PT, Conrad M, Bornkamm GW: The cystine/cysteine cycle: A redox cycle regulating susceptibility versus resistance to cell death. Oncogene 2008; 27: 1618-1628.
178. Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di TG, Clarke F, Sitia R, Rubartelli A: Antigenpresenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A 2002; 99: 1491-1496.
179. Yan Z, Garg SK, Kipnis J, Banerjee R: Extracellular redox modulation by regulatory T cells. Nat Chem Biol 2009; 5: 721-723.
180. Szatrowski TP, Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991; 51: 794-798.
181. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI: Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989-999.
182. Gringhuis SI, Leow A, Papendrecht-Van Der Voort EA, Remans PH, Breedveld FC, Verweij CL: Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis. J Immunol 2000; 164: 2170-2179.
183. Schmielau J, Finn OJ: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001; 61: 4756-4760.
184. Li W, Lidebjer C, Yuan XM, Szymanowski A, Backteman K, Ernerudh J, Leanderson P, Nilsson L, Swahn E, Jonasson L: NK cell apoptosis in coronary artery disease: relation to oxidative stress. Atherosclerosis 2008; 199: 65-72.
185. Mougiakakos D, Johansson CC, Kiessling R: Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood 2009; 113: 3542-3545.
186. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
187. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
188. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, Nelson DA, Jin S, White E: Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006; 10: 51-64.
189. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, Zeh HJ, Lotze MT: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29: 5299-5310.
190. Wild CA, Brandau S, Lindemann M, Lotfi R, Hoffmann TK, Lang S, Bergmann C: Toll-like receptors in regulatory T cells of patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2010; 136: 1253-1259.
191. Wild CA, Bergmann C, Fritz G, Schuler P, Hoffmann TK, Lotfi R, Westendorf A, Brandau S, Lang S: HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol 2012; 24: 485-494.
192. Wild CA, Brandau S, Lotfi R, Mattheis S, Gu X, Lang S, Bergmann C: HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 2012; 48: 409-416.
193. Savill J, Fadok V: Corpse clearance defines the meaning of cell death. Nature 2000; 407: 784-788.
194. Stuart LM, Lucas M, Simpson C, Lamb J, Savill J, Lacy-Hulbert A: Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J Immunol 2002; 168: 1627-1635.
195. Kuchler AM, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen DR, De Angelis PM, Scott H, Haraldsen G: Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 2008; 173: 1229-1242.
196. Lanier LL: DAP10-and DAP12-associated receptors in innate immunity. Immunol Rev 2009; 227: 150-160.
197. Chiang AC, Massague J: Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-2823.
198. Lee JJ, Lotze MT: Molecular basis of metastasis. N Engl J Med 2009; 360: 1679-1680.
199. Yasuda H: Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008; 19: 205-216.
200. Reth M: Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 2002; 3: 1129-1134.
201. Devadas S, Zaritskaya L, Rhee SG, Oberley L, Williams MS: Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression. J Exp Med 2002; 195: 59-70.
202. Gulow K, Kaminski M, Darvas K, Suss D, Li-Weber M, Krammer PH: HIV-1 trans-activator of transcription substitutes for oxidative signaling in activation-induced T cell death. J Immunol 2005; 174: 5249-5260.
203. Kwon J, Devadas S, Williams MS: T cell receptor-stimulated generation of hydrogen peroxide inhibits MEKERK activation and lck serine phosphorylation. Free Radic Biol Med 2003; 35: 406-417.
204. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA: Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 97: 3146-3151.
205. Harlin H, Hanson M, Johansson CC, Sakurai D, Poschke I, Norell H, Malmberg KJ, Kiessling R: The CD16-CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset. J Immunol 2007; 179: 4513-4519.
206. Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA: In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 1985; 134: 157-166.